Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes

Documenti analoghi

• GLP‐1 agonists and SGLT‐2 inhibitors in adults with sickle cell disease
  di: Ryan Sun, et al.
  Pubblicazione: (2024)
• SGLT‐2 inhibitors and GLP‐1 receptor agonists for Type 2 diabetes
  di: Esteban Davila, et al.
  Pubblicazione: (2024)
• The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
  di: Mario Luca Morieri, et al.
  Pubblicazione: (2026)
• Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis
  di: Sama M. Abdel‐Rahman, et al.
  Pubblicazione: (2026)
• One‐year usage patterns of SGLT ‐2 inhibitors and GLP ‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population
  di: Louise A. Donnelly, et al.
  Pubblicazione: (2025)